Company Encyclopedia
View More
name
Karyopharm Therap
KPTI.US
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds.
1.946 T
KPTI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking140/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE58.11%A
    • Profit Margin-87.43%E
    • Gross Margin25.85%C
  • Growth ScoreD
    • Revenue YoY-3.98%D
    • Net Profit YoY-42.46%D
    • Total Assets YoY-49.21%E
    • Net Assets YoY-68.66%E
  • Cash ScoreD
    • Cash Flow Margin-114.37%D
    • OCF YoY-3.98%D
  • Operating ScoreA
    • Turnover1A
  • Debt ScoreE
    • Gearing Ratio379.80%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Karyopharm Therapeutics Grants Stock Options and RSUs to New Employees

    Karyopharm Therapeutics Inc. has granted stock options for 2,800 shares and 15,791 RSUs to seven new employees. Stock options have a $5.62 exercise price and vest over four years, while RSUs vest over three years. Vesting is contingent on continued employment. This announcement was made via PR Newswire on December 01, 2025.

    Reuters·
    US
    KPTI
    +8.24%
    Reuters·
    US
    KPTI
    +8.24%

    Morning Trend | Karyopharm Therapeutics Major Activity, Is the Attack Window Coming?

    Karyopharm Therapeutics (KPTI.US) has experienced a long period of consolidation at low levels, and yesterday there were finally signs of significant buying activity during the trading session, leading to a sudden increase in trading sentiment in the community. Many short-term players rushed to buy around the $1.45 level, collectively anticipating that the main upward wave would "come as expected." The market shows that KPTI's shares have been circulating repeatedly in the $1.42-$1.50 range, with increasing signs of heavy control by the main players. As long as it breaks through $1.53 and stabilizes with increased volume, the short-term space is likely to open up easily. It is important to note that there is considerable divergence, with some players clearly taking profits at high points, and the sustainability of the rise still needs to be observed based on the main players' willingness to add positions. From a technical indicator perspective, the characteristics of a rebound from an oversold condition are evident and still in the early stages; if supported by capital, it is very likely to lead to an accelerated market. There are no significant negative factors in the fundamentals, and the short-term trading logic purely looks at the chip structure and sector trends. The strategy during the trading session suggests lightly testing the highs while closely monitoring whether the main players' large orders continue to buy in; otherwise, there could be a sudden pullback after a spike. The community generally expects a turning point this week to be very close, and aggressive traders may try to enter and exit quickly while maintaining key support lines. The main players' behavior in KPTI has shown significant volatility, and short-term opportunities are present in this window period

    Technical Forecast·
    US
    KPTI
    +8.24%
    Technical Forecast·
    US
    KPTI
    +8.24%

    Karyopharm Therapeutics Joins Piper Sandler Annual Healthcare Conference

    Karyopharm Therapeutics Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, with a fireside chat on December 4, 2025, at 10:30 a.m. ET in New York. A live webcast will be available on the company’s investor relations website. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    KPTI
    +8.24%
    Reuters·
    US
    KPTI
    +8.24%

    Karyopharm Therapeutics Highlights Selinexor Pipeline Progress and Myelofibrosis Opportunity in New Corporate Presentation

    Karyopharm Therapeutics Inc. has released a corporate presentation detailing the progress of its selinexor pipeline for cancer treatments, including myelofibrosis, multiple myeloma, and endometrial cancer. Selinexor is approved in 50 countries, with a potential $1 billion annual revenue for myelofibrosis. Phase 3 trial results are expected in 2026. The company reports strong commercial performance and a cash runway into Q2 2026.

    Reuters·
    US
    KPTI
    +8.24%
    Reuters·
    US
    KPTI
    +8.24%

    Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges

    Karyopharm Therapeutics' earnings call revealed progress in clinical trials and financial strategies, with a 13.4% revenue increase to $44 million in Q3 2025. The company completed enrollment in the Phase III SENTRY trial and secured $100 million through refinancing, extending its cash runway to Q2 2026. However, it reported a net loss of $33.1 million, primarily due to non-operational items, and faces challenges in a stagnant myelofibrosis market. Despite these hurdles, 75% of U.S. physicians showed intent to use its combination therapy, indicating strong market potential.

    Tip Ranks·
    US
    KPTI
    +8.24%
    Tip Ranks·
    US
    KPTI
    +8.24%
    © 2025 Longbridge｜Disclaimer